Navigation Links
Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
Date:9/7/2010

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences:


  • Morgan Stanley Global Healthcare ConferenceDate:  Tuesday, September 14, 2010 Time:  10:55am Eastern Time (7:55am Pacific Time)Place:  Grand Hyatt Hotel in New York City Speaker:  Ted Schroeder, President & CEO


  • Stifel Nicolaus Healthcare Conference 2010Date:  Thursday, September 16, 2010Time:  8:00am Eastern Time (5:00am Pacific Time)Place:  Four Seasons Hotel in BostonSpeaker:  Ted Schroeder, President & CEO


  • UBS Global Life Sciences ConferenceDate:  Wednesday, September 22, 2010Time:  10:00am Eastern Time (7:00am Pacific Time)Place:  Grand Hyatt Hotel in New York CitySpeaker:  William R. LaRue, SVP & CFO


  • JMP Securities Healthcare ConferenceDate:  Monday, September 27, 2010Time:  10:00am Eastern Time (7:00am Pacific Time)Place:  The New York Palace Hotel in New York CitySpeaker:  Ted Schroeder, President & CEOEach presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com on the Investor Relations page.  A replay of each webcast will available approximately three hours after the live webcast concludes and will remain available for 30 days.

    About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. For more information about Cadence, visit www.cadencepharm.com. Contacts:

    William R. LaRue

    SVP, CFOCadence Pharmaceuticals, Inc.

    858-436-1400
    '/>"/>


  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
    2. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
    3. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
    4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
    5. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
    6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
    7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
    8. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
    9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
    10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
    11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
    (Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
    (Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
    Breaking Medicine Technology:
    (Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
    (Date:4/24/2017)... ... April 24, 2017 , ... In ... be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into ... this type of healthcare model in the diagnosis and treatment of brain tumors. ...
    (Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant ... website. , Rod has been at the forefront of Gardant since it was founded ... Rod has overseen the opening of more than 40 new senior living communities. With ...
    (Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her ... good news for single women is that she put all the words in her ... 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her to ...
    (Date:4/24/2017)... ... April 24, 2017 , ... ... familiar. This makes it difficult for lab operators and management to assess these ... help them identify wasteful or unnecessary actions. , Created with the help ...
    Breaking Medicine News(10 mins):